PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 60
Summary
- Conditions
- Acute Myelogenous Leukemia
- B-cell Acute Lymphoblastic Leukemia
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Chronic Myeloid Leukemia, Blast Crisis
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02730312
- Collaborators
- ICON Clinical Research
- Investigators
- Study Director: Allen S. Yang, MD, PhD Senior VP & Chief Medical Officer, Xencor, Inc.